Article Text

Download PDFPDF

4CPS-124 Cost optimisation plan in immunotherapy
  1. A Planas Giner,
  2. A Sosa-Pons,
  3. L Cardona-Roca,
  4. N Rudi-Sola
  1. Hospital General de Granollers, Pharmacy Department, Granollers, Spain


Background and importance Three years ago, posology of nivolumab 3 mg/kg was modified in the Summary of Product Characteristics (SmPC) for a fixed dose (flat-dose) of 240 mg every 2 weeks or 480 mg every 4 weeks after showing equivalence.

Aim and objectives The aim of the study was to assess the potential cost savings if we used individualised dose by weight (3 mg/kg) and apply flat-dose (240 mg or 480 mg) in those patients weighing 80 kg or more.

Material and methods Retrospective study conducted in a second-level general hospital that included all patients treated with nivolumab during 1 year (2020).

A database was designed with the following variables: age, sex, weight, diagnosis, dosage regimen and drug costs expressed in laboratory sale price.

After applying the cost optimisation plan, the dosage of the patients was grouped according to weight: ≥80 kg use of flat-dose and <80 kg use of individualised dose of 3 mg/kg.

Costs of administering nivolumab according to an individualised dose of 3 mg/kg and the flat-dose regimen were calculated.

Results During the study period, 37 patients were treated with nivolumab, 29 received a fixed dose of 240 mg every 2 weeks and eight fixed doses of 480 mg monthly. Patients’ mean weight was 71.1 kg (range 52–119). Drug’s total cost was €1 258 560 per year.

Applying the individualised dose of 3 mg/kg in all patients, the cost would be reduced to €1 177 620, generating a saving of €80 940.

Applying the individualised dose of 3 mg/kg and scheduling treatment administration on a single day a week, the cost would be €1 116 558.75, obtaining a saving of €142 002.

In addition to the above measures, setting the dose at 240 mg in those patients weighing ≥80 kg, the cost would be reduced to €1 090 096.50, generating a saving of €168 463.50. Applying this method, based on body weight, only six patients would maintain flat-dose while 31 would require an individualised dose.

Conclusion and relevance The use of individualised nivolumab doses may be a good strategy for optimising treatment costs. The combined use of flat-dose with individualised dose based on patients’ weight would reduce the cost associated with nivolumab by 13.4%, corresponding to about €168 000 per year.

Conflict of interest No conflict of interest

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.